SCHEMBL16933633

SCHEMBL16933633

CC1(COc2ccc(-c3ccc(C(C)(C)NC(=O)N4CCN5CCC4CC5)cc3)cc2)COC1

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 3/20 0.39
▸ ACACB O00763 1/20 0.36
▸ CHRNA3 P32297 2/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ HTR3A P46098 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16933694 0.82 CHRNA7 (0.40) CHRNA7ACACBCHRNA3
SCHEMBL16933443 0.82 CHRNA7 (0.37) CHRNA7ACACBCHRNA3HTR3A
SCHEMBL16933550 0.81 CHRNA7 (0.39) CHRNA7ACACB
SCHEMBL29387778 0.81 NTMT1 (0.42) FLT3
SCHEMBL19924063 0.79 ACACB (0.44) ACACB
SCHEMBL15578119 0.79 NTMT1 (0.49) —
SCHEMBL16933454 0.76 HRH3 (0.45) —
SCHEMBL16933668 0.75 CHRNA7 (0.37) CHRNA7HTR3A
SCHEMBL16933606 0.75 ATP4A (0.37) CHRNA7
SCHEMBL16933605 0.74 MLYCD (0.43) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 — — US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 — — US disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 — — EP disclosed
CN-114533729-A Glucosylceramide synthase inhibitors 建新公司 2022-05-27 — — CN disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 — — US disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 — — EP disclosed
CN-108864076-B Glucosylceramide synthase inhibitors 建新公司 2022-02-11 — — CN disclosed
US-11008316-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2021-05-18 — — US disclosed
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2018-03-08 — — US disclosed
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885ACACB 132/4885CHRNA3 4411/4885
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885ACACB 132/4885CHRNA3 4411/4885
US-11008316-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GAA CHRNA7 4652/4885ACACB 106/4885CHRNA3 4629/4885
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC CHRNA7 4254/4885ACACB 276/4885CHRNA3 4196/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885ACACB 132/4885CHRNA3 4411/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885ACACB 132/4885CHRNA3 4411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback